ilaprazole   Click here for help

GtoPdb Ligand ID: 10512

Synonyms: IY-81149 | IY81149 | Noltec®
Approved drug
ilaprazole is an approved drug (South Korea, China)
Compound class: Synthetic organic
Comment: Ilaprazole (IY-81149) is an irreversible proton pump inhibitor (PPI) [2]. It is a prodrug that is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the proton pump H+/K+ ATPase of gastric parietal cells, and thereby inhibits gastric acid secretion [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 91.49
Molecular weight 366.12
XLogP 1.13
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccnc(c1C)CS(=O)c1nc2c([nH]1)cc(cc2)n1cccc1
Isomeric SMILES COc1ccnc(c1C)CS(=O)c1nc2c([nH]1)cc(cc2)n1cccc1
InChI InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)
InChI Key HRRXCXABAPSOCP-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Ilaprazole is available in south Korea, China, Mexico and India as treatment for dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and duodenal ulcer [1,4]. It has not yet received US FDA or EMA authorisations (October 2019). Click here to link to ClinicalTrials.gov's full list of ilaprazole studies.
Pharmacokinetics Click here for help
Biotransformation/Metabolism
Predictions based on results using human liver microsomes indicate minimal risk of ilaprazole drug-drug interaction via CYP3A4 inhibition/induction when co-administered with other drugs [3].
Elimination
Non-enzymatic sulfoxide reduction is the major metabolic clearance pathway of ilaprazole in humans [3].